Soluble interleukin-2 receptors in Hodgkin's disease
Author Information
Author(s): S Viviani, E Camerini, V Bonfante, A Santoro, M Balzarotti, M Fornier, L Devizzi, P Verderio, P Valagussa, G Bonadonna
Primary Institution: Istituto Nazionale Tumori, Milano, Italy
Hypothesis
The study aims to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease in relation to complete remission and disease relapse.
Conclusion
The study confirms that patients with untreated Hodgkin's disease have increased baseline levels of sIL-2R compared to healthy subjects, and these levels correlate with disease outcome.
Supporting Evidence
- Patients with untreated Hodgkin's disease had significantly higher sIL-2R levels than healthy controls.
- 135 out of 137 evaluated patients achieved complete response (CR) after treatment.
- After a median follow-up of 5 years, sIL-2R levels remained low in 114 patients in continuous CR.
- An increase in sIL-2R levels was observed in 75% of patients who relapsed.
Takeaway
Doctors measured a special protein in the blood of people with Hodgkin's disease to see if it could help predict how well they would do after treatment.
Methodology
sIL-2R serum levels were measured in 174 untreated patients before treatment, after treatment in 137 patients, and during follow-up in 132 patients.
Limitations
Not all patients with relapse showed increased sIL-2R levels, and some increases were observed in non-neoplastic conditions.
Participant Demographics
{"median_age":28,"age_range":"16-69","gender_distribution":{"men":90,"women":84},"histology":{"nodular_sclerosis":132,"others":42},"b_symptoms":{"no":95,"yes":79},"nodal_involvement":140,"extranodal_involvement":34,"bulky_disease":{"no":131,"yes":43}}
Statistical Information
P-Value
0.0001
Confidence Interval
95% confidence interval 1.15-1.18
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website